AIHTA - Publications - Search - Zolbetuximab (Vyloy®) with chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2‑negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma

Rothschedl, E. and Grössmann, N. (2024): Zolbetuximab (Vyloy®) with chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2‑negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma. Fact Sheet Nr. 186.

[thumbnail of Fact Sheet Nr.186.pdf]
Preview
 PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
158kB

Item Type:Horizon Scanning of Medicines
Subjects:QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
QZ Pathology > QZ 200-380 Neoplasms.Cysts
WB Practice of medicine > WB 300-962 Therapeutics
WI Digestive system > WI 250 Oesophagus
WI Digestive system > WI 300-387 Stomach
Language:English
Series Name:Fact Sheet Nr. 186
Deposited on:24 Sep 2024 10:37
Last Modified:24 Sep 2024 10:37

Repository Staff Only: item control page